{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:53:57Z","timestamp":1779886437086,"version":"3.53.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00520-021-06535-9","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T05:02:26Z","timestamp":1632546146000},"page":"1681-1687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Xerostomia: an immunotherapy-related adverse effect in cancer patients"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6476-0904","authenticated-orcid":false,"given":"Hannah","family":"Bustillos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Indorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Alwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"issue":"9","key":"6535_CR1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8(9):1069\u20131086","journal-title":"Cancer Discov"},{"issue":"9","key":"6535_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563\u2013580","journal-title":"Nat Rev Clin Oncol"},{"key":"6535_CR3","unstructured":"National Comprehensive Cancer Network. Management of immunotherapy-related toxicities (Version 1.2020). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf. Accessed October 5, 2020"},{"issue":"17","key":"6535_CR4","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17):1714\u20131768","journal-title":"J Clin Oncol"},{"issue":"5","key":"6535_CR5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.clindermatol.2017.06.010","volume":"35","author":"JW Millsop","year":"2017","unstructured":"Millsop JW, Wang EA, Fazel N (2017) Etiology, evaluation, and management of xerostomia. Clin Dermatol. 35(5):468\u2013476","journal-title":"Clin Dermatol."},{"issue":"1","key":"6535_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.17219\/acem\/29375","volume":"25","author":"M Tanasiewicz","year":"2016","unstructured":"Tanasiewicz M, Hildebrandt T, Obersztyn I (2016) Xerostomia of various etiologies: a review of the literature. Adv Clin Exp Med. 25(1):199\u2013206","journal-title":"Adv Clin Exp Med."},{"key":"6535_CR7","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1007\/s00520-015-2720-y","volume":"23","author":"S Mercadante","year":"2015","unstructured":"Mercadante S, Aielli F, Adile C et al (2015) Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients. Support Care Cancer 23:3249\u20133255","journal-title":"Support Care Cancer"},{"key":"6535_CR8","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1007\/s00520-019-4650-6","volume":"27","author":"B Garc\u00eda-Ch\u00edas","year":"2019","unstructured":"Garc\u00eda-Ch\u00edas B, Figuero E, Castelo-Fern\u00e1ndez B et al (2019) Prevalence of oral side effects of chemotherapy and its relationship with periodontal risk: a cross sectional study. Support Care Cancer 27:3479\u20133490","journal-title":"Support Care Cancer"},{"issue":"5","key":"6535_CR9","doi-asserted-by":"publisher","first-page":"e00322","DOI":"10.1002\/rcr2.322","volume":"6","author":"S Takahashi","year":"2018","unstructured":"Takahashi S, Chieko X, Sakai T et al (2018) Nivolumab-induced sialadenitis. Respirol Case Rep 6(5):e00322","journal-title":"Respirol Case Rep"},{"issue":"9","key":"6535_CR10","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","volume":"24","author":"BM Warner","year":"2019","unstructured":"Warner BM, Baer AN, Lipson EJ et al (2019) Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 24(9):1259\u20131269","journal-title":"Oncologist"},{"key":"6535_CR11","unstructured":"LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury. [Updated 2019 May 4].\u00a0Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548069\/.\u00a0Accessed 5 Oct 2020"},{"issue":"3","key":"6535_CR12","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1136\/annrheumdis-2016-210820","volume":"77","author":"S Le Burel","year":"2018","unstructured":"Le Burel S, Champiat S, Routier E et al (2018) Onset of connective tissue disease following anti-PD1\/PD-L1 cancer immunotherapy. Ann Rheum Dis 77(3):468\u2013470","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6535_CR13","first-page":"114","volume":"37 Suppl 118","author":"M Ramos-Casals","year":"2019","unstructured":"Ramos-Casals M, Maria A, Su\u00e1rez-Almazor ME et al (2019) Sicca\/Sj\u00f6gren\u2019s syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clin Exp Rheumatol 37 Suppl 118(3):114\u2013122","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"6535_CR14","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1634\/theoncologist.2019-0467","volume":"25","author":"A Ortiz Brugu\u00e9s","year":"2020","unstructured":"Ortiz Brugu\u00e9s A, Sibaud V, Herbault-Barr\u00e9s B et al (2020) Sicca syndrome induced by immune checkpoint inhibitor therapy: optimal management still pending. Oncologist 25(2):e391\u2013e395","journal-title":"Oncologist"},{"issue":"1","key":"6535_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","volume":"76","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Baer AN et al (2017) Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 76(1):43\u201350","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"6535_CR16","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/S0885-3924(01)00318-9","volume":"22","author":"AN Davies","year":"2001","unstructured":"Davies AN, Broadley K, Beighton D (2001) Xerostomia in patients with advanced cancer. J Pain Symptom Manage 22(4):820\u2013825","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"6535_CR17","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.adaj.2015.09.014","volume":"147","author":"CQ Cheng","year":"2016","unstructured":"Cheng CQ, Xu H, Liu L et al (2016) Efficacy and safety of pilocarpine for radiation-induced xerostomia in patients with head and neck cancer: a systematic review and meta-analysis. J Am Dent Assoc 147(4):236\u2013243","journal-title":"J Am Dent Assoc"},{"issue":"6","key":"6535_CR18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1056\/NEJM199308053290603","volume":"329","author":"JT Johnson","year":"1993","unstructured":"Johnson JT, Ferretti GA, Nethery WJ et al (1993) Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 329(6):390\u2013395","journal-title":"N Engl J Med"},{"issue":"2","key":"6535_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archinte.159.2.174","volume":"159","author":"FB Vivino","year":"1999","unstructured":"Vivino FB, Al-Hashimi I, Khan Z et al (1999) Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sj\u00f6gren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92\u201301 Study Group. Arch Intern Med 159(2):174\u201381","journal-title":"Arch Intern Med"},{"issue":"4","key":"6535_CR20","first-page":"575","volume":"32","author":"G Noaiseh","year":"2014","unstructured":"Noaiseh G, Baker JF, Vivino FB (2014) Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sj\u00f6gren\u2019s syndrome. Clin Exp Rheumatol 32(4):575\u20137","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"6535_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/00044011-200222020-00001","volume":"22","author":"H Yasuda","year":"2002","unstructured":"Yasuda H, Niki H (2002) Review of the pharmacological properties and clinical usefulness of muscarinic agonists for xerostomia in patients with Sj\u00f6gren\u2019s syndrome. Clin Drug Investig 22(2):67\u201373","journal-title":"Clin Drug Investig"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06535-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06535-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06535-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T09:15:57Z","timestamp":1641287757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06535-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["6535"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06535-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]},"assertion":[{"value":"27 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was granted approval by the University of Washington Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Obtaining consent to participate was not required for this retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Obtaining consent for publication was not required for this retrospective study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}